Patient info Search Menu

Xylonor spray 150 mg / g + 1.5 mg / g Oromucosal spray solution – patient leaflet, side effects, dosage

Updated:
Medicine strength:
150 mg / g + 1.5 mg / g
Contains active substance:

Patient leaflet - Xylonor spray 150 mg / g + 1.5 mg / g Oromucosal spray solution

1. What XYLONOR SPRAY is and what it is used for

XYLONOR SPRAY is used to obtain a local anaesthesia of the lining of the inside of the mouth (buccal mucosa) before performing dental procedures.

It contains two active ingredients:

  • lidocaine, a local anaesthetic, which numbs the painful

    area temporarily,

  • cetrimide, an antiseptic, which kills any micro‐organisms

    that are present.

XYLONOR SPRAY is for children over 6 years old and adults. Only a dentist or stomatologist can administer this product.

2. What you need to know before you use XYLONOR SPRAY

For professional use by dentists and stomatologists only.

Do not use XYLONOR SPRAY

  • if you are allergic to lidocaine or cetrimide or to any of the

    other ingredients of this medicine (listed in section 6). ▪ if you are allergic to other local anaesthetics called amide

    type anaesthetics.

  • in children under 6 years old.

Warning and precautions

  • Before receiving this medicine, tell your dentist or stoma‐

    tologist if you have severe infection or an inflammation in the area to be treated.

  • The dentist should avoid spraying the back of the throat.

Children

This medicinal product should not be used below 6 years old.

Other medicines and XYLONOR SPRAY

Tell your dentist if:

  • you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription.
  • you have injuries in your mouth because lidocaine may be released into the blood and interact with other medicines.

Xylonor with food

After using this medicine, avoid chewing gum or eating until normal sensation is restored, otherwise you risk biting your lips, cheeks or tongue.

Pregnancy, breast‐feeding and fertility

If you are pregnant or breast‐feeding, think you may be pregnant or are planning to have a baby, ask your dentist, doctor or pharmacist for advice before taking this medicine. XYLONOR SPRAY can be used during pregnancy and breastfeeding without any risk to the foetus or to the breastfed child, provided that it is used as prescribed.

No effects on fertility are anticipated.

Driving and using machine

XYLONOR SPRAY has no or negligible influence on the ability to drive and use machines.

XYLONOR SPRAY contains alcohol (ethanol 96%)

This medicine contains 606 mg of alcohol (ethanol 96%) in a maximum daily dose of 1.3 g of product which is equivalent to 45.45% (w/w). It may cause a slight burning sensation when exposed to open wounds.

3. How to use XYLONOR SPRAY

Only dentists and stomatologists are trained to use XYLONOR SPRAY.

Your dentist will explain to you why you are being treated with XYLONOR SPRAY.

He or she will adjust the dosage according to your age, your health and the treatment you are having.

The minimum effective anaesthetic dose should be used. Your dentist will spray it onto the buccal mucosa. XYLONOR SPRAY should not be sprayed in the back of throat.

Use in children and adolescents

Particular care should be taken when treating children and adolescents.

Your dentist will adjust the dosage according to the child’s age and weight.

If your dentist or stomatologist use more XYLONOR SPRAY than they should

Under normal conditions of use in dentistry, no overdose effects are to be expected with a product for local use only. However, the following symptoms may be signs of toxicity due to excessive doses or rapid absorption of the product: burning, pricking, tingling sensations around the mouth with no apparent physical cause, dizziness, nervousness, anxiety, apprehension, euphoric mood, confusion, drowsiness, oversensitivity of hearing, ringing in the ears, blurred vision, vomiting, nausea, feeling hot, cold or numbed, muscle twitching, tremors, fits, loss of consciousness, abnormally slow breathing or suspension of breathing, abnormally slow or irregular heartbeat, low blood pressure.

09/23 05 06 033 15 00 Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

ͳ Keep this leaflet. You may need to read it again. ͳ If you have any further questions, ask your dentist, doc‐

tor or pharmacist.

ͳ If you get any side effects, talk to your dentist, doctor or

pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

If you experience any of these, talk to your dentist, doctor or pharmacist.

If you swallow a lot of the solution, or if you think your child has swallowed any of the solution, tell your dentist. If you have any further questions on the use of this medicine, ask your dentist, doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

While you are in your dentist’s office, your dentist will carefully follow the effects of XYLONOR SPRAY.

Inform your dentist, doctor or pharmacist immediately if you experience one of the following serious side effects, which might be symptoms of a hypersensitivity reaction (aller-gic / allergic‐like reaction):

  • skin rash, hives or itching, skin irritation and occasionally

    sensitisation.

  • swelling of the face, lips, gums, tongue and/or throat, diffi‐

    culty breathing, wheezing, asthma.

These side effects happen rarely (they may affect up to 1 in 1,000 people).

Other side effects may also occur in some patients (frequency not known (cannot be estimated from the available data):

  • Rash, redness,
  • Itching,
  • Exfoliation and ulceration of the gums,
  • Abnormal sensation in and around the mouth,
  • Swelling of the application site, application site burn.

Reporting of side effects

If you get any side effects, talk to your dentist, doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store XYLONOR SPRAY

Keep this medicine out of the sight and reach of children. It is most unlikely that you will be asked to look after this medicine.

Your dentist will not use this medicine after the expiry date which is stated on the package after EXP. The expiry date refers to the last day of that month.

Your dentist will keep it up to 25°C.

Do not throw away any medicines via wastewater or household waste. Ask your dentist or pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What XYLONOR SPRAY contains

  • The active substances are Lidocaine 10 mg per dose and

    Cetrimide 0.10 mg per dose

  • The other ingredients are: saccharin, spearmint flavour, dipropylene glycol and ethanol 96%.

What XYLONOR SPRAY looks like and content of the pack

It is a clear, colourless to slightly yellow liquid with an odour of mint.

XYLONOR SPRAY is available in metered dose aerosol containing 36 g of solution.

Marketing authorisation holder

Septodont Ltd, Units R & S

Orchard Business Centre

St Barnabas Close

Allington, Maidstone

Kent ME16 0JZ ‐ UK

Manufacturer

Septodont

58 rue du Pont de Créteil

94100 Saint‐Maur‐des‐Fossés

France

This leaflet was last revised in 08/2023.

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 08313/0032

Last revision stated in the text: August 2023 · MHRA data as of 13 October 2026

What the sections and the side effect frequencies mean: How to read a patient leaflet

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Xylonor spray 150 mg / g + 1.5 mg / g Oromucosal spray solution

What these facts mean

Active substance? Cetrimide
Strength? 150 mg / g + 1.5 mg / g
Drug group (ATC)?
  1. N Nervous system drugs
    1. N01 Anesthetics
      1. N01B Local anesthetics
        1. N01BB Amide local anesthetics
          1. N01BB52 lidocaine, combinations
Marketing authorisation? PL 08313/0032

Sources: the MHRA product information (products.mhra.gov.uk). Contains public sector information licensed under the Open Government Licence v3.0.